Search Results for

S2000

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Continue Reading »

---

Nektar 20-214-29

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Continue Reading »

---

EA6192

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Continue Reading »

---

MK7902-003

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

Continue Reading »

---

A091802

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Continue Reading »

---

S1801

Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery

Continue Reading »

---

EA6134

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Continue Reading »

---

Search Again

• All Trial Categories Anal  (3) Bladder/Urinary Tract Cancer  (8)    Adjuvant  (1)    Metastatic  (2)    Neoadjuvant  (4) Brain  (7)    Glioblastoma Multiforme (GBM)  (3)    Other Brain Tumors  (3) Breast  (17)    1st Line Metastatic Breast, Metastasis at Presentation or Progression of earlier Disease  (5)    2nd Line Metastatic Breast, Progressive Disease Following 1st Line Therapy  (1)    Breast Cancer Adjuvant  (5)    Breast Cancer Neoadjuvant  (1)    DCIS/LCIS  (1) Cancer Control/Symptom Management  (21) Carcinoid Tumors  (2) Colorectal Cancer  (9)    Metastatic  (4) Esophageal Cancer  (2) Gastric Cancer  (2)    Metastaic Gastric Cancer  (1) Head/Neck Cancer  (4)    Resectable Oral Cavity Cancer  (1)       Primary Chemoradiation Regimens  (1) Leukemia  (5)    Acute Myeloid Leukemia (AML)  (1)    B-Cell Chromic Lymphocytic Leukemia (CLL) / Small Ly  (3) Liver/Hepatocellular Carcinoma  (1) Lung Cancer  (24)    Non-Small Cell Lung Cancer  (18)       1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence  (4)       2nd Line Metastatic, Stage 4 Patients with Progressive Disease  (3)       Adjuvant Treatment for Resected NSCLC  (4)    Small Cell Lung Cancer  (6)       Extensive Stage SCLC  (3) Lymphoma  (8)    Non-Hodgkin’s Lymphoma  (4)       Diffuse Large B-Cell Lymphoma  (1)       Follicular Lymphoma  (3)          Relapsed/Refractory  (3) MATCH Trial  (1) MDS  (3) Melanoma  (7)    Metastatic  (3) Merkel Cell Carcinoma  (1) Multiple Myeloma  (1) Pancreatic  (6)    Metastatic Disease  (4) Prostate  (8) Renal Cell/Kidney Cancer  (6)    Locally Advanced/Metastatic  (4) Sarcoma  (2) Small Bowel  (1)